How did the announcement affect AtaiBeckley's stock?

The stock surged 33.4% to $7.22, a four-year high.

What are Eli Lilly's motives for acquiring AtaiBeckley?

Eli Lilly aims to strengthen its pipeline in mental health and neurological treatments.

Are there any expected regulatory challenges for the deal?

No specific challenges have been announced, but the deal will undergo regulatory review.

Eli Lilly Acquires AtaiBeckley in $3.8 Billion Deal

Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion, driving ATAI stock to its highest level in four years.

July 17, 2026

2 min read

Source: Insider Monkey

Key Numbers

deal value

3.8B

stock price high

7.22

daily gain percent

33.40

Eli Lilly and Company (NYSE: LLY) announced the acquisition of AtaiBeckley (NASDAQ: ATAI) in a deal valued at up to $3.8 billion. Shares of AtaiBeckley surged 33.4% during the session to reach $7.22, a four-year high.

Deal Details

Item	Value
Total deal value	$3.8 billion
Target share price	Not disclosed
Premium to last close	Not disclosed
Expected form	Cash and stock (unconfirmed)

Rationale

Eli Lilly aims to bolster its pipeline in mental health and neurological treatments through this acquisition. AtaiBeckley has an innovative platform for developing drugs for disorders such as depression and anxiety. The deal aligns with Lilly's strategy to expand into new therapeutic areas.

Regulatory Challenges

The acquisition is expected to undergo review by regulatory bodies such as the FTC and SEC. No specific regulatory hurdles have been announced yet.

Impact on Stocks

AtaiBeckley shares jumped sharply following the announcement, while Eli Lilly shares remained relatively unchanged. Investors await further details on deal terms and closing timeline.

Frequently Asked Questions

The deal is valued at $3.8 billion.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.